Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$95.63

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $95.63 5

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $68.88 4
Boehringer Ingelheim Pharmaceuticals, Inc. $26.75 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $95.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $13.8808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921203 CMS
Janssen Pharmaceuticals, Inc $17.8705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921205 CMS
Janssen Pharmaceuticals, Inc $17.8705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921201 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.7503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763507670 CMS
Janssen Pharmaceuticals, Inc $19.2602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

183 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $9,240.00 12/31/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792489179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423691
Principal investigator 1 GlaxoSmithKline, LLC. $1,222.65 12/21/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544621
Principal investigator 1 GlaxoSmithKline, LLC. $792.00 12/15/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809500953
Principal investigator 1 ABBVIE INC. $128.00 12/10/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486787
Principal investigator 1 ABBVIE INC. $2,430.50 12/09/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486333
Principal investigator 1 ABBVIE INC. $2,555.60 12/07/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792485823
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $50.14 12/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423653
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 11/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809514005
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809500923
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809500947
Principal investigator 1 GlaxoSmithKline, LLC. $4,654.00 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809501059
Principal investigator 1 GlaxoSmithKline, LLC. $1,243.44 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809513865
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809513999
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 11/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529509
Principal investigator 1 ABBVIE INC. $6,142.40 11/09/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481933
Principal investigator 1 ABBVIE INC. $384.00 11/04/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481221
Principal investigator 1 ABBVIE INC. $1,009.40 11/04/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792481261
Principal investigator 1 GlaxoSmithKline, LLC. $1,525.59 11/03/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529467
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 11/03/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264513
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 11/03/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264517
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.14 11/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388035
Principal investigator 1 GlaxoSmithKline, LLC. $792.00 11/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809500941
Principal investigator 1 GlaxoSmithKline, LLC. $2,189.88 11/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809513859
Principal investigator 1 GlaxoSmithKline, LLC. $792.00 11/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423633
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 10/20/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544675
Principal investigator 1 GlaxoSmithKline, LLC. $792.00 10/20/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $440.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $0.50 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/18/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423425
Principal investigator 1 GlaxoSmithKline, LLC. $1,584.00 10/13/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809500935
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 10/13/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544669
Principal investigator 1 ABBVIE INC. $1,854.80 10/07/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792478199
Principal investigator 1 ABBVIE INC. $380.91 10/06/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792477541
Principal investigator 1 GlaxoSmithKline, LLC. $7,621.02 10/06/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544629
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.22 10/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388037
Principal investigator 1 GlaxoSmithKline, LLC. $1,217.35 10/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 860867967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,450.00 09/24/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 09/24/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423497
Principal investigator 1 GlaxoSmithKline, LLC. $1,891.89 09/22/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809497311
Principal investigator 1 GlaxoSmithKline, LLC. $3,237.30 09/22/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809542847
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,730.00 09/22/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264469
Principal investigator 1 GlaxoSmithKline, LLC. $6,038.01 09/15/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809509047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 09/13/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423313
Principal investigator 1 ABBVIE INC. $128.00 09/09/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474789
Principal investigator 1 ABBVIE INC. $2,823.30 09/08/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474385
Principal investigator 1 ABBVIE INC. $1,300.60 09/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792473711
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.26 09/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388039
Principal investigator 1 GlaxoSmithKline, LLC. $2,941.29 09/01/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423339
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 08/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809513853
Principal investigator 1 GlaxoSmithKline, LLC. $1,222.65 08/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809513887
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 08/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529361
Principal investigator 1 GlaxoSmithKline, LLC. $823.68 08/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529431
Principal investigator 1 GlaxoSmithKline, LLC. $823.68 08/24/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809544599
Principal investigator 1 GlaxoSmithKline, LLC. $4,299.57 08/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 08/11/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 08/11/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 08/11/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 08/11/2021 Non-covered Recipient Entity
Pharmax Research Clinic
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423341
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.64 08/10/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809501051
Principal investigator 1 Eli Lilly and Company $936.00 08/09/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819462461
Principal investigator 1 GlaxoSmithKline, LLC. $2,725.07 08/06/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 809521001
Principal investigator 1 GlaxoSmithKline, LLC. $27,686.34 08/03/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
Not supplied No dispute reported 06/30/2026 809529385
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.52 08/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388041
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $130.00 07/31/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388025
Principal investigator 1 ABBVIE INC. $192.00 07/29/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469555
Principal investigator 1 ABBVIE INC. $4,142.50 07/29/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469557
Principal investigator 1 ABBVIE INC. $1,000.00 07/29/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792469981
Principal investigator 1 ABBVIE INC. $5,865.10 07/29/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792469983
Principal investigator 1 GlaxoSmithKline, LLC. $8,915.98 07/27/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 809509887
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 07/15/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264467
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,548.00 07/09/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264463
Principal investigator 1 ABBVIE INC. $1,347.20 07/08/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792466999
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.46 07/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388029
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 06/11/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264431
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $800.00 06/08/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388023
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $800.00 06/08/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388033
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $54.13 06/01/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388031
Principal investigator 1 ABBVIE INC. $1,970.10 05/27/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792460301
Principal investigator 1 ABBVIE INC. $850.00 05/27/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
24-Hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Receiving Testosterone Replacement Therapy No dispute reported 06/30/2026 792460627
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $659.28 05/26/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex-3 No dispute reported 06/30/2026 828388027
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,210.20 05/21/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264437
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $250.00 05/21/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264441
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80.00 05/05/2021 Non-covered Recipient Entity
Pharmax Research Clinic
Connex 3 No dispute reported 06/30/2026 840492803
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819449189
Principal investigator 1 Eli Lilly and Company $350.00 04/30/2021 Non-covered Recipient Entity
NECCR PRIMA CARE RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819460601
Principal investigator 1 ABBVIE INC. $6,461.50 04/29/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792448729
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,863.80 04/28/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264443
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,703.40 04/22/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470011
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 04/16/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264435
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,044.10 04/08/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264427
Principal investigator 1 ABBVIE INC. $3,368.00 03/30/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792436919
Recipient Eli Lilly and Company $437.46 03/29/2021 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819444917
Principal investigator 1 Eli Lilly and Company $3,309.51 03/17/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819466459
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $401.40 03/05/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264411
Principal investigator 1 ABBVIE INC. $12,723.50 03/02/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792427765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,863.80 02/19/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264407
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 02/18/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264421
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,663.10 02/11/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264405
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,178.00 02/04/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264397
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,317.40 02/04/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264401
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $617.00 02/04/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264415
Principal investigator 1 ABBVIE INC. $5,195.30 01/28/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792414221
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,927.50 01/27/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264395
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,381.80 01/21/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264391
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 01/15/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264417
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.70 01/07/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.70 01/07/2021 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806264705